Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

23.10.2007
New Cancer Targets, New Therapeutics and Clinical Trials

Merging technological innovations and new knowledge about basic cancer biology, cancer researchers now target specific molecules involved in critical chemical pathways of cancerous cells.

The approach opens the door to more effective drug therapies and treatment strategies, advances that will be the focus of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics – the premier international meeting featuring novel cancer therapeutics – to be held October 22 to 26 at the Moscone West Convention Center, San Francisco, California.

Each year, the American Association for Cancer Research (AACR), jointly with the National Cancer Institute (NCI) and the European Organisation for Research and Treatment of Cancer (EORTC), brings together scientists and other professionals from around the world seeking to share the latest information in this field, otherwise known as molecular targets of cancer.

“We are in the midst of a remarkable period of exploration and experimentation in cancer research, with tools and technologies in place to put into practice what might only have been theory just a few short years ago,” said Sara A. Courtneidge, Ph.D., a co-chairperson on the Scientific Committee for the meeting and professor at The Burnham Institute for Medical Research in La Jolla, California. “This meeting – where researchers can talk face-to-face about the latest information and reports from continuing studies – is a necessary part of the process of scientific discovery.”

More than 3,000 scientists and clinicians – from the laboratories of universities, medical centers and pharmaceutical companies worldwide – are gathering in San Francisco to present and discuss novel cancer research findings. The AACR has selected 24 scientific abstracts for presentation by their authors in five press briefings, each highlighting a critical or emerging area of molecular target research, such as:

•The promising results of a Phase I trial of a novel antibody against the insulin-like growth factor receptor in patients with advanced solid tumors have prompted researchers based at the University of Colorado Health Sciences Center to initiate a Phase II trial.

•Screening the NCI’s vast Natural Products Repository for the next Taxol is a complicated task with innumerable rewards. The National Cancer Institute maintains the world’s largest database of natural compounds, representing biologically diverse organisms from across the globe. However, screening these unpurified samples involves complicated chemistry. NCI researchers have used advanced screening techniques to uncover a way of “throwing a monkey wrench” into a cell process responsible for a great percentage of human cancers.

•Combining therapies to deliver a “one-two punch” against cancer is rapidly coming to fruition in cancer research. Combining approved targeted treatments with other existing and emerging therapies may enhance the effects of the individual treatments, alone. Researchers at the University of Manchester have found, for example, that combining radiotherapy with an inhibitor under development can prevent cancer cells from becoming resistant to radiation.

•The discovery of new targets for cancer therapeutics, when combined with high-throughput screening techniques, has made it possible for researchers to rapidly develop new drug candidates that might serve as therapies in multiple cancers. Scientists from ARIUS Research have created a novel antibody that effectively “de-cloaks” cancer cells, enabling the immune system to recognize and attack tumors. Likewise, researchers from University College London have identified the first small molecule inhibitors of protein kinase D, a frequently deregulated pathway in many cancers.

Nicole Heine | alfa
Further information:
http://www.eortc.be

More articles from Event News:

nachricht ICTM Conference 2017: Production technology for turbomachine manufacturing of the future
16.11.2016 | Fraunhofer-Institut für Produktionstechnologie IPT

nachricht Innovation Day Laser Technology – Laser Additive Manufacturing
01.11.2016 | Laser Zentrum Hannover e.V.

All articles from Event News >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Simple processing technique could cut cost of organic PV and wearable electronics

06.12.2016 | Materials Sciences

3-D printed kidney phantoms aid nuclear medicine dosing calibration

06.12.2016 | Medical Engineering

Robot on demand: Mobile machining of aircraft components with high precision

06.12.2016 | Power and Electrical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>